 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Gambro AB
|
-
New structure to strengthen growth
(11/02/2006)
The Gambro Group will develop into three independent companies. Gambro Renal Products will become the new Gambro. Gambro Healthcare and Gambro BCT will gradually become independent companies with formal Boards of Directors and independent governance ...
-
Gambro and DaVita reach agreement on Amended Alliance and Product Supply Agreement
(08/30/2006)
Gambro AB, Gambro Renal Products, Inc. and DaVita Inc. have agreed to an amended and restated Alliance and Product Supply Agreement. This amendment effectively revokes the termination notice which was provided by DaVita in May primarily as a result ...
-
Jan Bruneheim new President and CEO for Gambro
(07/20/2006)
Sören Mellstig, Gambro's current President and CEO, and Gambro's new Board of Directors have agreed on that Sören Mellstig will leave his position. Jan Bruneheim, 52, has been appointed new President and CEO for Gambro. Jan Bruneheim will take ...
-
Gambro acquires Hemapure
(05/11/2006)
Gambro announced that it intends to acquire the assets and operations of Hemapure AB. All employees will transfer to Gambro. Hemapure has developed a new innovative port system for vascular access for renal patients. Gambro will through the ...
-
Gambro and Nephrogen - new partner for regenerative medicine program
(10/25/2005)
Gambro has recently signed an agreement with Nephrogen, LLC as part of its Regenerative Medicine initiative announced earlier this year. The program will extend over a period of three years with the target to restore the function of the kidney using ...
-
Gambro expands into the emerging market for liver support
(09/21/2004)
Gambro acquires the business of Teraklin AG, Germany, and expands its intensive care business into the extracorporeal treatments for liver support. The transaction is subject to approval by a creditors' committee of Teraklin. Teraklin develops, ...
-
Navigant Biotechnologies awarded additional USD 2 M Department of Defense research funding
(08/30/2004)
Gambro's wholly owned subsidiary, Navigant Biotechnologies, Inc., announces that the U.S. Department of Defense (DOD) has awarded it an additional USD 2 million grant to continue to develop and test its Mirasol(TM) Pathogen Reduction Technology ...
-
Gambro to focus pathogen reduction development
(02/26/2004)
Navigant Biotechnologies, Inc. ("Navigant"), a Denver, US based company and wholly owned subsidiary of Gambro AB, is focusing its Mirasol pathogen reduction technology for application to platelets and red blood cells. Pathogen reduction refers to ...
Additional information
Gambro AB
Stockholm, Sweden
Company
|
|
|
|
|
|
Top
